Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

As the dust settles on a phase 3 announcement that added $45 billion to Moderna’s market cap, analysts have begun to ask a ...

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...

Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of ...

Moderna's melanoma mRNA vaccine had a major Phase 3 breakthrough. Here's what's next and when it could become available for skin cancer patients.

Moderna and Merck have been running a large Phase III trial in over a thousand high-risk patients who had already had surgery ...

Moderna Inc. MRNA stock is trading lower after it rallied around 170% on Wednesday on upbeat data from individualized cancer ...

Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said on Wednesday, ...

Moderna MRNA stock fell 20%% to $138, compared with Wednesday’s close of $174.38. The decline followed a more than doubling ...

Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...